

**WHAT IS CLAIMED IS:**

1. A composition for the treatment of asthma, the composition comprising:

a first receptor antagonist and a second receptor antagonist, said first and second receptor antagonists being selected from the group consisting of leukotriene receptor antagonists and histamine receptor antagonists; and  
an adrenergic bronchodilator.

2. The composition of Claim 1, wherein said adrenergic bronchodilator is a beta<sub>2</sub>-adrenergic bronchodilator.

3. The composition of Claim 2, wherein said beta<sub>2</sub>-adrenergic bronchodilator is albuterol sulfate.

4. The composition of Claim 1, wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast sodium and zafirlukast sodium.

5. The composition of Claim 1, wherein said histamine receptor is a histamine H<sub>1</sub>-receptor antagonist.

6. The composition of Claim 5, wherein said histamine H<sub>1</sub>-receptor antagonist is selected from the group consisting of ceterizine hydrochloride, loratadine, and fexofenadine.

7. A composition for treatment of asthma, the composition comprising:

a first receptor antagonist having a first chemical composition;

a second receptor antagonist having a second chemical composition, said first chemical composition and said second chemical composition being chemically dissimilar; and

an adrenergic bronchodilator.

8. The composition of Claim 7, wherein said first receptor antagonist and said second receptor antagonist are selected from the group consisting of leukotriene receptor antagonists and histamine receptor antagonists.

9. The composition of Claim 8, wherein said adrenergic bronchodilator is a beta<sub>2</sub>-adrenergic bronchodilator.

10. The composition of Claim 9, wherein said beta<sub>2</sub>-adrenergic bronchodilator is albuterol sulfate.

11. The composition of Claim 8, wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast sodium and zafirlukast sodium.

12. The composition of Claim 8, wherein said histamine receptor is a histamine H<sub>1</sub>-receptor antagonist.

13. The composition of Claim 12, wherein said histamine H<sub>1</sub>-receptor antagonist is selected from the group of consisting ceterizine hydrochloride, loratadine, and fexofenadine.

14. A composition for the treatment of asthma, the composition comprising:

montelukast sodium;

an antihistamine selected from the group consisting of cetirizine, loratadine, and fexofenadine; and

a sympathomimetic bronchodilator.

15. The composition of Claim 14, wherein said sympathomimetic bronchodilator is albuterol.

16. A method for treating asthma comprising the steps of:  
preparing a composition comprising:  
a first receptor antagonist in the amount of between about 4.0 mg  
and about 20.0 mg;  
a second receptor antagonist in the amount of between about 2.5  
mg and about 180.0 mg, said second receptor antagonist being  
different from said first receptor antagonist;  
an adrenergic bronchodilator in the amount of between about 4.0  
mg and about 8.0 mg; and  
administering said composition to a patient.

17. The method of Claim 16, wherein said first receptor antagonist and  
said second receptor antagonist are selected from the group consisting of  
leukotriene receptor antagonists and histamine receptor antagonists.

18. The method of Claim 16, wherein said adrenergic bronchodilator is  
a beta<sub>2</sub>-adrenergic bronchodilator.

19. The composition of Claim 18, wherein said beta<sub>2</sub>-adrenergic  
bronchodilator is albuterol sulfate.

20. The composition of Claim 17, wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast sodium and zafirlukast sodium.

21. The composition of Claim 17, wherein said histamine receptor is a histamine H<sub>1</sub>-receptor antagonist.

22. The composition of Claim 21, wherein said histamine H<sub>1</sub>-receptor antagonist is selected from the group consisting of ceterizine hydrochloride, loratadine, and fexofenadine.